Literature DB >> 20130472

Molecular epidemiology of HIV-1 subtype B, CRF01_AE, and CRF07_BC infection among injection drug users in Taiwan.

Yen-Ju Chen1, Yu-Huei Huang, Shao-Yuan Chuang, Diana Yu-Ting Kao, Yu-Ching Lan, Jyh-Yuan Yang, Yi-Ming Arthur Chen.   

Abstract

OBJECTIVE: An explosive outbreak of HIV-1 circulating recombinant form (CRF) 07_BC among injection drug users (IDUs) in Taiwan was first reported in 2004 and reach the peak in 2005. The objectives of this study were to investigate the molecular epidemiology of different HIV-1 subtypes and their associated risk factors among Taiwanese IDUs in 2004 and 2005.
METHODS: Questionnaires and blood specimens were collected from inmates from 4 detention centers and 2 prisons. HIV-1 subtypes were determined using nested polymerase chain reactions with multiplex primers and phylogenetic analyses. A case-control study was conducted to elucidate risk factors associated with CRF07_BC infection.
RESULTS: A total of 93.8%, 4%, and 2.2% of 451 inmates with IDU history were infected with CRF07_BC, subtype B, and CRF01_AE, respectively. Besides CRF07_BC, a new outbreak of CRF01_AE infection was identified among IDUs from central region. Multivariate analysis showed that sharing dissolved heroine solution [odds ratio (OR) = 17.2], sharing syringes (OR = 34), number of persons sharing syringes (2 vs. 1, OR = 3.1), and lower educational level (OR = 2.3) were risk factors associated with CRF07_BC infection.
CONCLUSIONS: Sharing dissolved heroine solution is a neglected risk factor associated with HIV-1 infection and it should be emphasized in the AIDS education and harm reduction programs immediately.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130472     DOI: 10.1097/QAI.0b013e3181ccba1a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

Review 1.  Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia.

Authors:  Georgios K Nikolopoulos; Evangelia-Georgia Kostaki; Dimitrios Paraskevis
Journal:  Infect Genet Evol       Date:  2016-06-07       Impact factor: 3.342

2.  Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B.

Authors:  Rebecca A Oyomopito; Patrick C K Li; Somnuek Sungkanuparph; Praphan Phanuphak; Kok Keng Tee; Thira Sirisanthana; Pacharee Kantipong; Shinichi Oka; Chris K C Lee; Adeeba Kamarulzaman; Jun Yong Choi; Annette H Sohn; Matthew Law; Yi-Ming A Chen
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

3.  Increased genetic diversity of HIV-1 circulating in Hong Kong.

Authors:  Jonathan Hon-Kwan Chen; Ka-Hing Wong; Zhiwei Chen; Kenny Chan; Ho-Yin Lam; Sabrina Wai-Chi To; Vincent Chi-Chung Cheng; Kwok-Yung Yuen; Wing-Cheong Yam
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

4.  Molecular Epidemiology of HIV-1 Infection among Men who Have Sex with Men in Taiwan in 2012.

Authors:  Szu-Wei Huang; Sheng-Fan Wang; Ángel E Cowó; Marcelo Chen; Yu-Ting Lin; Chun-Po Hung; Yi-Hsien Chen; Jyh-Yuan Yang; Hung-Jen Tang; Yi-Ming Arthur Chen
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

5.  Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.

Authors:  Szu-Wei Huang; Wei-You Li; Wen-Hung Wang; Yu-Ting Lin; Chih-Hung Chou; Marcelo Chen; Hsien-Da Huang; Yen-Hsu Chen; Po-Liang Lu; Sheng-Fan Wang; Shinichi Oka; Yi-Ming Arthur Chen
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

6.  Ascertaining the 2004-2006 HIV type 1 CRF07_BC outbreak among injecting drug users in Taiwan.

Authors:  Ying-Hen Hsieh
Journal:  Int J Infect Dis       Date:  2013-02-12       Impact factor: 3.623

7.  Effects of education on harm-reduction programmes.

Authors:  Shu-Yu Lyu; Lien-Wen Su; Yi-Ming Arthur Chen
Journal:  Lancet       Date:  2011-08-16       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.